Evidence map›Paper›PMID 39893165›Full record

ArticleNature communications2025

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies.

Yan-Ruide Li, Ying Fang, Siyue Niu, Yichen Zhu, Yuning Chen, Zibai Lyu, Enbo Zhu, Yanxin Tian, Jie Huang, Valerie Rezek and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Allogeneic CD56Journal of cancer research and clinical oncology · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yan-Ruide Li *Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-9858-300X
Ying Fang *Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Siyue Niu *Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Yichen Zhu *Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Yuning ChenDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0000-8010-670X
Zibai LyuDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Enbo ZhuDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-8600-8553
Yanxin TianDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Jie HuangDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Valerie RezekDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2336-7599
Scott KitchenDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-6182-6082
Tzung HsiaiDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-1734-0792
Jin J ZhouDepartment of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, USA.
Pin WangDepartment of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-4132-105X
Wanxing Chai-HoDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Sunmin ParkDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Christopher S SeetDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-4821-1400
Caspian OliaiDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Lili YangDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA. liliyang@ucla.edu.ORCID http://orcid.org/0000-0001-6568-0404

Funding

UCLA-CDU CFARP30AI152501 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SCOTT G KITCHEN · 2022 to 2026
$15.6M
Shear Stress and Light-Sheets to Study Cardiac TrabeculationR01HL129727 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSIAI, TZUNG K, MARSDEN, ALISON L · 2015 to 2024
$3.5M
Caltech/UCLA Individualized Theranostic Engineering to Advance Metabolic System (iTEAM)T32EB027629 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Dino Di Carlo, Azita Emami · 2020 to 2026
$2.0M
Integrating Volumetric Light-Field with Computational Fluid Dynamics to Study Myocardial Trabeculation and FunctionR01HL159970 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSIAI, TZUNG K, MARSDEN, ALISON L · 2021 to 2024
$2.0M
UCLA and Caltech integrated Cardiovascular Medicine for Bioengineers (iCMB)T32HL144449 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSIAI, TZUNG K, PAJUKANTA, PAIVI · 2020 to 2024
$1.2M
California Institute for Regenerative Medicine (CIRM) DISC2-11157California Institute for Regenerative Medicine (CIRM) TRAN1-12250NHLBI NIH HHS R01 HL129727NHLBI NIH HHS R01 HL159970NHLBI NIH HHS T32 HL144449NIAID NIH HHS P30 AI152501NIBIB NIH HHS T32 EB027629UC | University of California, Los Angeles (UCLA) Ablon Scholars AwardUC | University of California, Los Angeles (UCLA) CIRM-BSCRC Postdoctoral FellowshipUC | University of California, Los Angeles (UCLA) UCLA BSCRC Innovation AwardUC | University of California, Los Angeles (UCLA) UCLA Chancellor's Award for Postdoctoral ResearchUC | University of California, Los Angeles (UCLA) UCLA MIMG M. John Pickett Post-Doctoral Fellow AwardUC | University of California, Los Angeles (UCLA) UCLA Sydney Finegold Postdoctoral AwardU.S. Department of Defense (United States Department of Defense) CDMRP PRCRP Impact Award (CA200456)
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR)-engineered T cell therapy holds promise for treating myeloid malignancies, but challenges remain in bone marrow (BM) infiltration and targeting BM-resident malignant cells. Current autologous CAR-T therapies also face manufacturing and patient selection issues, underscoring the need for off-the-shelf products. In this study, we characterize primary patient samples and identify a unique therapeutic opportunity for CAR-engineered invariant natural killer T (CAR-NKT) cells. Using stem cell gene engineering and a clinically guided culture method, we generate allogeneic CD33-directed CAR-NKT cells with high yield, purity, and robustness. In preclinical mouse models, CAR-NKT cells exhibit strong BM homing and effectively target BM-resident malignant blast cells, including CD33-low/negative leukemia stem and progenitor cells. Furthermore, CAR-NKT cells synergize with hypomethylating agents, enhancing tumor-killing efficacy. These cells also show minimal off-tumor toxicity, reduced graft-versus-host disease and cytokine release syndrome risks, and resistance to allorejection, highlighting their substantial therapeutic potential for treating myeloid malignancies.

Indexed as

Immunotherapy, AdoptiveReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 3AnimalsBone MarrowFemaleGraft vs Host DiseaseHumansMiceXenograft Model Antitumor AssaysCD33 protein, humanReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 3

Identifiers

PMID39893165
PMCPMC11787387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.